Delayed trial readouts
Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.
Summary
521 date moves in Phase 3 and 2/3 studies: 323 later and 198 earlier. The median move later is 183 days.
Date moves
| Seen | Drug | Study | Phase | Old date | New date | Move |
|---|---|---|---|---|---|---|
| 2026-11-20 | Ferric derisomaltose | NCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy | Phase 3 | 2026-12-31 | 2026-05-31 | −214 days |
| 2026-11-19 | tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), Bictegravir | NCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed | Phase 2/3 | 2028-01 | 2026-11-03 | −424 days |
| 2026-11-19 | PF-08634404, Pembrolizumab | NCT06980272SSGJ-707 in Advanced Non-Small Cell Lung Cancer | Phase 3 | 2026-07-30 | 2026-02-01 | −179 days |
| 2026-11-19 | tilrekimig | NCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time | Phase 3 | 2034-05-12 | 2034-04-21 | −21 days |
| 2026-11-18 | INCB123667 | NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 3 | 2028-11-15 | 2027-10-12 | −400 days |
| 2026-11-18 | Gemcitabine, Atezolizumab | NCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Phase 3 | 2027-06-01 | 2026-07-23 | −313 days |
| 2026-11-18 | Depemokimab | NCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | Phase 3 | 2029-04-30 | 2029-04-02 | −28 days |
| 2026-11-18 | Inclisiran | NCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Phase 3 | 2027-02-11 | 2027-01-16 | −26 days |
| 2026-11-18 | Tafolecimab | NCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | 2026-09-06 | 2026-08-26 | −11 days |
| 2026-11-17 | Daraxonrasib, Nab-paclitaxel, Gemcitabine | NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | 2028-06 | 2028-04 | −61 days |
| 2026-11-14 | Oxycodone (Xtampza ER) | NCT04659317Opioid-Free Orthopaedics | Phase 3 | 2028-12 | 2026-07-20 | −865 days |
| 2026-11-14 | BGM0504 | NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Phase 3 | 2026-11-14 | 2026-08-13 | −93 days |
| 2026-11-14 | BGM0504, Semaglutide (Ozempic) | NCT06716216A Study of BGM0504 in Participants With Type 2 Diabetes | Phase 3 | 2026-11-14 | 2026-08-25 | −81 days |
| 2026-11-14 | maralixibat | NCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | 2026-10 | 2026-07-29 | −64 days |
| 2026-11-14 | Bempedoic acid | NCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | Phase 3 | 2025-10 | 2025-08-05 | −57 days |
| 2026-11-13 | Naloxone (Narcan) | NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment | Phase 3 | 2026-08-31 | 2026-01-30 | −213 days |
| 2026-11-13 | Vosoritide | NCT06455059Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | Phase 3 | 2026-08-01 | 2026-04-23 | −100 days |
| 2026-11-13 | barzolvolimab | NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Phase 3 | 2026-10 | 2026-08-04 | −58 days |
| 2026-11-13 | barzolvolimab | NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Phase 3 | 2026-10 | 2026-08-12 | −50 days |
| 2026-11-13 | Bofanglutide | NCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects | Phase 3 | 2026-05 | 2026-03-26 | −36 days |
| 2026-11-13 | Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, Carfilzomib | NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | 2026-08-30 | 2026-08-26 | −4 days |
| 2026-11-13 | setmelanotide | NCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Phase 3 | 2025-12-22 | 2025-12-19 | −3 days |
| 2026-11-11 | Pelacarsen | NCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | 2028-08-24 | 2026-10-15 | −679 days |
| 2026-11-11 | Bofanglutide | NCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Phase 3 | 2027-09 | 2026-09-22 | −344 days |
| 2026-11-11 | Bofanglutide, Semaglutide (Ozempic) | NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Phase 3 | 2026-12-11 | 2026-09-18 | −84 days |
| 2026-11-11 | Tirzepatide (Zepbound) | NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Phase 2/3 | 2027-01-01 | 2026-10-10 | −83 days |
| 2026-11-11 | Ranibizumab, Bevacizumab | NCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) | Phase 3 | 2026-07 | 2026-05-28 | −34 days |
| 2026-11-11 | retatrutide | NCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | 2027-07 | 2027-06 | −30 days |
| 2026-11-11 | Aflibercept | NCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Phase 3 | 2026-10 | 2026-09-09 | −22 days |
| 2026-11-11 | Cabotegravir/rilpivirine (Cabenuva) | NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed | Phase 3 | 2029-09-04 | 2029-08-13 | −22 days |
| 2026-11-11 | Bofanglutide | NCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise | Phase 3 | 2026-08-07 | 2026-07-30 | −8 days |
| 2026-11-11 | metreleptin | NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL | Phase 3 | 2026-07-21 | 2026-07-14 | −7 days |
| 2026-11-11 | rilzabrutinib | NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Phase 3 | 2026-11-30 | 2026-11-25 | −5 days |
| 2026-11-10 | remibrutinib | NCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | Phase 3 | 2031-10-29 | 2031-10-15 | −14 days |
| 2026-11-10 | Ruxolitinib (Opzelura) | NCT06958211Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Phase 3 | 2026-10-09 | 2026-10-01 | −8 days |
| 2026-11-10 | tralokinumab | NCT06311682A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis | Phase 3 | 2026-10-20 | 2026-10-16 | −4 days |
| 2026-11-08 | Rituximab, Obinutuzumab | NCT05786768Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome | Phase 2/3 | 2027-10-18 | 2027-06-30 | −110 days |
| 2026-11-07 | Trontinemab | NCT07717411A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Phase 3 | 2032-09-03 | 2032-07-30 | −35 days |
| 2026-11-07 | Cemdisiran, Pozelimab, Eculizumab, Ravulizumab | NCT05133531A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | Phase 3 | 2026-10-12 | 2026-09-28 | −14 days |
| 2026-11-06 | Quetiapine (Seroquel), Clozapine, valproate, Esketamine | NCT05603104Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | Phase 3 | 2028-06-30 | 2026-06-24 | −737 days |
| 2026-11-05 | Capecitabine | NCT05065957Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | Phase 2/3 | 2026-07 | 2025-07-31 | −335 days |
| 2026-11-05 | fluticasone propionate | NCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | 2026-11-02 | 2026-10-26 | −7 days |
| 2026-11-04 | jaktinib | NCT05526222A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis | Phase 3 | 2026-06 | 2025-08-05 | −300 days |
| 2026-11-04 | Tobevibart (VIR-3434) | NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Phase 3 | 2026-12-31 | 2026-09-30 | −92 days |
| 2026-11-03 | Docetaxel, Gemcitabine, Eribulin mesylate, Sacituzumab Govitecan | NCT04579224Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | 2030-08-15 | 2026-03-05 | −1624 days |
| 2026-11-03 | Entrectinib, Alectinib, Durvalumab | NCT05170204A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 2030-06-16 | 2027-01-19 | −1244 days |
| 2026-11-03 | Lanifibranor | NCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | 2027-09-30 | 2026-09-29 | −366 days |
| 2026-11-03 | Dexamethasone | NCT05132920Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage | Phase 3 | 2024-12 | 2024-09-09 | −83 days |
| 2026-11-01 | Nab-paclitaxel | NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Phase 2/3 | 2029-01-15 | 2027-12-01 | −411 days |
| 2026-11-01 | Docetaxel, Gemcitabine, Risvutatug rezetecan | NCT06935409Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | Phase 3 | 2026-08-31 | 2026-06-17 | −75 days |
| 2026-11-01 | Risvutatug rezetecan | NCT06498479ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2026-08-20 | −41 days |
| 2026-11-01 | Docetaxel | NCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | 2031-06-17 | 2031-05-30 | −18 days |
| 2026-10-31 | Vericiguat | NCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | 2032-04-15 | 2029-08-20 | −969 days |
| 2026-10-31 | Trastuzumab Deruxtecan | NCT07022483A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting | Phase 3 | 2032-03-23 | 2030-02-26 | −756 days |
| 2026-10-31 | Tadalafil | NCT05195775Tadalafil as Adjuvant Therapy for DMD | Phase 2/3 | 2025-09-05 | 2024-04-16 | −507 days |
| 2026-10-31 | Methylprednisolone | NCT04163536Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU | Phase 3 | 2025-10-25 | 2024-11-24 | −335 days |
| 2026-10-31 | tocilizumab, Methotrexate | NCT03892785MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial | Phase 3 | 2027-01 | 2026-03-27 | −280 days |
| 2026-10-31 | Sacituzumab Tirumotecan | NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Phase 3 | 2027-01-04 | 2026-10-19 | −77 days |
| 2026-10-31 | Rademikibart | NCT06488755SIM0718 Treatment of Asthma Clinical Study | Phase 3 | 2027-02-28 | 2026-12-31 | −59 days |
| 2026-10-31 | Ranibizumab | NCT06957080A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Phase 2/3 | 2027-03-01 | 2027-01-11 | −49 days |
| 2026-10-24 | Aficamten | NCT07023341A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 3 | 2026-08-31 | 2026-07-14 | −48 days |
| 2026-10-24 | pemetrexed | NCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Phase 3 | 2026-10-31 | 2026-09-22 | −39 days |
| 2026-10-23 | Gemcitabine | NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Phase 2/3 | 2029-01-15 | 2027-12-01 | −411 days |
| 2026-10-23 | Docetaxel | NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Phase 3 | 2027-01-04 | 2026-10-19 | −77 days |
| 2026-10-22 | Dexamethasone, CT-P44, Lenalidomide, Daratumumab | NCT06952478A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | Phase 3 | 2027-11-15 | 2027-03-08 | −252 days |
| 2026-10-21 | SHR-1918 | NCT07349615A Study of SHR-1918 In Participants With Hypertriglyceridemia | Phase 3 | 2027-11 | 2027-03 | −245 days |
| 2026-10-20 | Methotrexate | NCT05600426A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) | Phase 3 | 2029-12 | 2026-08-06 | −1213 days |
| 2026-10-20 | Aflibercept | NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | 2028-11 | 2027-11 | −366 days |
| 2026-10-17 | Benralizumab | NCT06750289Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | 2028-11-03 | 2026-09-21 | −774 days |
| 2026-10-17 | dupilumab, upadacitinib | NCT06461897A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | Phase 3 | 2030-07 | 2029-11 | −242 days |
| 2026-10-17 | lamivudine (Epivir-HBV), Dolutegravir | NCT04022967ANRS 12372 MODERATO Study | Phase 3 | 2025-02-05 | 2024-12-30 | −37 days |
| 2026-10-17 | Cenobamate | NCT05067634Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | Phase 3 | 2026-11 | 2026-10-02 | −30 days |
| 2026-10-17 | Baxdrostat | NCT07007793Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. | Phase 3 | 2027-08-13 | 2027-07-27 | −17 days |
| 2026-10-16 | Capecitabine, Fulvestrant, Eribulin mesylate, Alpelisib (BYL719) | NCT05063786Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) | Phase 3 | 2026-06 | 2025-12-23 | −160 days |
| 2026-10-16 | Telitacicept | NCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | 2027-05 | 2027-03 | −61 days |
| 2026-10-16 | Fulvestrant, Capivasertib | NCT06764186A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain | Phase 3 | 2027-12-31 | 2027-11-30 | −31 days |
| 2026-10-16 | Saruparib | NCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | 2031-06-17 | 2031-05-30 | −18 days |
| 2026-10-15 | Capecitabine | NCT04495088Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer | Phase 3 | 2030-08 | 2026-07-31 | −1462 days |
| 2026-10-15 | Nivolumab, Atezolizumab | NCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Phase 3 | 2028-04-06 | 2027-08-17 | −233 days |
| 2026-10-15 | Everolimus | NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Phase 3 | 2027-08-04 | 2026-12-30 | −217 days |
| 2026-10-15 | IncobotulinumtoxinA (Xeomin) | NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | Phase 3 | 2027-10 | 2027-03 | −214 days |
| 2026-10-15 | PF-08634404 | NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Phase 2/3 | 2032-01-15 | 2031-07-22 | −177 days |
| 2026-10-15 | Montelukast (Singulair) | NCT06113640Montelukast in Parkinson Disease | Phase 2/3 | 2026-11-20 | 2026-08-20 | −92 days |
| 2026-10-15 | Calcipotriene/Betamethasone Dipropionate Cream | NCT07357831A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects | Phase 3 | 2026-10-10 | 2026-08-06 | −65 days |
| 2026-10-15 | Haloperidol, Olanzapine (Zyprexa) | NCT07246187Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department | Phase 3 | 2026-10-31 | 2026-09-25 | −36 days |
| 2026-10-15 | Capecitabine, Datopotamab Deruxtecan, Durvalumab, Pembrolizumab | NCT05629585A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | Phase 3 | 2027-09-20 | 2027-09-01 | −19 days |
| 2026-10-15 | Ruxolitinib (Jakafi), Bomedemstat | NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | Phase 3 | 2027-07-30 | 2027-07-14 | −16 days |
| 2026-10-15 | Omalizumab | NCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks | Phase 3 | 2028-06-02 | 2028-05-24 | −9 days |
| 2026-10-14 | diazoxide choline | NCT05701774Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome | Phase 3 | 2028-06 | 2026-01-12 | −871 days |
| 2026-10-14 | Docetaxel | NCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 2031-04 | 2030-03 | −396 days |
| 2026-10-14 | Nivolumab | NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Phase 2/3 | 2032-01-15 | 2031-07-22 | −177 days |
| 2026-10-14 | Atezolizumab, Bevacizumab | NCT05482516Evaluating Novel Therapies in ctDNA Positive GI Cancers | Phase 3 | 2026-12 | 2026-08-20 | −103 days |
| 2026-10-14 | Depemokimab | NCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | Phase 3 | 2027-11-24 | 2027-10-29 | −26 days |
| 2026-10-14 | remibrutinib | NCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks | Phase 3 | 2028-06-02 | 2028-05-24 | −9 days |
| 2026-10-14 | Esomeprazole | NCT05267613Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. | Phase 3 | 2026-08-14 | 2026-08-10 | −4 days |
| 2026-10-14 | ustekinumab | NCT05299931An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study | Phase 3 | 2026-06 | 2026-05-29 | −3 days |
| 2026-10-10 | pemetrexed, Volrustomig, Pembrolizumab | NCT05984277A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Phase 3 | 2029-02-28 | 2026-08-17 | −926 days |
| 2026-10-10 | sonelokimab | NCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | Phase 3 | 2027-02-04 | 2026-05-28 | −252 days |
| 2026-10-10 | sonelokimab, risankizumab | NCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | 2027-01-15 | 2027-01-04 | −11 days |
| 2026-10-09 | Bevacizumab, Atezolizumab | NCT03148418A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | Phase 3 | 2026-12-31 | 2026-11-30 | −31 days |
| 2026-10-07 | Lecanemab | NCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Phase 3 | 2029-06-30 | 2026-12-31 | −912 days |
| 2026-10-07 | maridebart cafraglutide | NCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Phase 3 | 2027-09-03 | 2027-08-20 | −14 days |
| 2026-10-07 | tilrekimig | NCT07772921A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma | Phase 3 | 2029-06-12 | 2029-06-01 | −11 days |
| 2026-10-06 | Telisotuzumab Adizutecan, Ramucirumab | NCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 2031-04 | 2030-03 | −396 days |
| 2026-10-06 | Calderasib, Pembrolizumab | NCT06345729A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | Phase 3 | 2029-02-19 | 2028-01-24 | −392 days |
| 2026-10-06 | Depemokimab | NCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Phase 3 | 2029-08-21 | 2028-12-13 | −251 days |
| 2026-10-06 | Depemokimab | NCT06959095Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation | Phase 3 | 2029-08-20 | 2028-12-13 | −250 days |
| 2026-10-06 | Emestedastat | NCT06125951Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | Phase 2/3 | 2026-10 | 2026-09-22 | −9 days |
| 2026-10-03 | afimkibart | NCT06588855A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 3 | 2027-01-30 | 2026-10-29 | −93 days |
| 2026-10-03 | Anifrolumab | NCT07691970Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment | Phase 3 | 2032-12-31 | 2032-12-30 | −1 day |
| 2026-10-02 | Mepolizumab | NCT05030155Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) | Phase 3 | 2025-11 | 2025-02-21 | −253 days |
| 2026-10-01 | zanubrutinib, Rituximab | NCT04002297A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | Phase 3 | 2027-03 | 2026-04-27 | −308 days |
| 2026-10-01 | Ranibizumab | NCT06571045A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Phase 2/3 | 2026-09-30 | 2026-07-14 | −78 days |
| 2026-10-01 | Selinexor | NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | 2026-08 | 2026-05-22 | −71 days |
| 2026-10-01 | Fitusiran | NCT03754790Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | Phase 3 | 2026-11-05 | 2026-09-14 | −52 days |
| 2026-10-01 | Dapagliflozin | NCT06750458Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients | Phase 3 | 2026-10-20 | 2026-09-20 | −30 days |
| 2026-09-30 | maridebart cafraglutide | NCT07226765Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Phase 3 | 2027-09-29 | 2027-08-30 | −30 days |
| 2026-09-29 | Lenacapavir (Sunlenca), Bictegravir | NCT06532656Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 | Phase 2/3 | 2030-07 | 2026-11 | −1338 days |
| 2026-09-29 | Rimegepant (Nurtec ODT) | NCT05156398Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects | Phase 3 | 2031-11-29 | 2029-03-27 | −977 days |
| 2026-09-29 | Gemcitabine, Rinatabart sesutecan (Rina-S) | NCT06619236Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | 2027-02 | 2026-08-18 | −167 days |
| 2026-09-29 | Palbociclib, Anastrozole, Camizestrant | NCT04711252A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | Phase 3 | 2026-08-24 | 2026-06-26 | −59 days |
| 2026-09-29 | Bevacizumab, PF-08634404 | NCT07222800Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Phase 3 | 2030-03-29 | 2030-02-23 | −34 days |
| 2026-09-26 | Cangrelor | NCT04667078REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts | Phase 3 | 2030-03-01 | 2026-12-21 | −1166 days |
| 2026-09-26 | Trontinemab | NCT07169578A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | 2028-06-07 | 2028-02-16 | −112 days |
| 2026-09-26 | Trontinemab | NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | 2028-06-07 | 2028-02-16 | −112 days |
| 2026-09-26 | Dexamethasone, Bortezomib, Teclistamab, Pomalidomide, Daratumumab | NCT05083169A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | 2025-09-15 | 2025-08-01 | −45 days |
| 2026-09-25 | Benralizumab | NCT05692180A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | Phase 3 | 2030-05-05 | 2026-12-23 | −1229 days |
| 2026-09-25 | lunsekimig | NCT07793409A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | 2031-10-28 | 2031-07-23 | −97 days |
| 2026-09-25 | Capecitabine, Zanidatamab, Tislelizumab | NCT05152147A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | Phase 3 | 2026-09-30 | 2026-07-15 | −77 days |
| 2026-09-24 | Tremelimumab, Bevacizumab, Atezolizumab, Durvalumab, Budigalimab | NCT06109272A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | Phase 2/3 | 2030-09 | 2027-01 | −1339 days |
| 2026-09-24 | Vicadrostat, Empagliflozin | NCT06531824EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Phase 3 | 2028-08-30 | 2026-12-31 | −608 days |
| 2026-09-24 | Dexamethasone, Etentamig, Lenalidomide, Daratumumab | NCT07095452A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Phase 2/3 | 2042-01 | 2040-09 | −487 days |
| 2026-09-24 | pemetrexed, Rilvegostomig, Datopotamab Deruxtecan | NCT06564844A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | Phase 3 | 2027-06-30 | 2026-07-10 | −355 days |
| 2026-09-24 | jaktinib | NCT05861102Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) | Phase 3 | 2026-05 | 2025-06-09 | −326 days |
| 2026-09-24 | Dexamethasone, Lenalidomide, Daratumumab | NCT03993912Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy | Phase 3 | 2026-10-07 | 2026-08-28 | −40 days |
| 2026-09-24 | Tenapanor (Ibsrela) | NCT05643534Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | Phase 3 | 2026-09-01 | 2026-08-20 | −12 days |
| 2026-09-24 | Benralizumab | NCT07444567Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment | Phase 3 | 2030-01-03 | 2029-12-27 | −7 days |
| 2026-09-24 | Tamoxifen (Soltamox) | NCT06440967A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | Phase 3 | 2026-06-30 | 2026-06-25 | −5 days |
| 2026-09-24 | Lenbelintide | NCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | Phase 3 | 2028-08-09 | 2028-08-08 | −1 day |
| 2026-09-22 | dupilumab | NCT04244006A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome | Phase 2/3 | 2024-06-01 | 2022-06-01 | −731 days |
| 2026-09-22 | Dapagliflozin | NCT05986136Dapagliflozin in Patients With Ulcerative Colitis | Phase 2/3 | 2027-08-20 | 2026-08-20 | −365 days |
| 2026-09-22 | tenofovir alafenamide (Vemlidy), Ulonivirine, Islatravir, Bictegravir | NCT07266831A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) | Phase 2/3 | 2029-03-21 | 2029-02-01 | −48 days |
| 2026-09-19 | maridebart cafraglutide | NCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Phase 3 | 2027-09-29 | 2027-09-03 | −26 days |
| 2026-09-19 | Zilebesiran | NCT07181109Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | Phase 3 | 2030-09-30 | 2030-09-23 | −7 days |
| 2026-09-17 | Letrozole | NCT06418347Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females | Phase 3 | 2025-11-01 | 2025-08-01 | −92 days |
| 2026-09-17 | Finerenone | NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | Phase 3 | 2028-10-08 | 2028-08-01 | −68 days |
| 2026-09-15 | Atezolizumab | NCT04543617A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | Phase 3 | 2027-03-31 | 2026-07-22 | −252 days |
| 2026-09-15 | Motixafortide | NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | Phase 3 | 2026-12-31 | 2026-09-11 | −111 days |
| 2026-09-15 | orforglipron | NCT06649045A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Phase 3 | 2026-11 | 2026-07-21 | −103 days |
| 2026-09-12 | Balcinrenone, Dapagliflozin | NCT06307652Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | 2027-06-11 | 2027-04-16 | −56 days |
| 2026-09-12 | Ravulizumab | NCT07557420Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 3 | 2028-10-31 | 2028-09-19 | −42 days |
| 2026-09-12 | Ravulizumab | NCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | Phase 3 | 2027-08-27 | 2027-08-17 | −10 days |
| 2026-09-11 | Ziltivekimab | NCT05636176A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | 2027-07-02 | 2026-09-03 | −302 days |
| 2026-09-11 | deucravacitinib | NCT04036435Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis | Phase 3 | 2026-07-25 | 2026-07-21 | −4 days |
| 2026-09-10 | Trastuzumab rezetecan, Docetaxel, Pertuzumab | NCT06057610A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer | Phase 3 | 2027-10 | 2026-07-15 | −443 days |
| 2026-09-10 | Efimosfermin alfa | NCT07701993A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 3 | 2033-07-27 | 2033-06-23 | −34 days |
| 2026-09-05 | Depemokimab | NCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | Phase 3 | 2028-12-19 | 2027-11-24 | −391 days |
| 2026-09-05 | remibrutinib | NCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | Phase 3 | 2031-10-27 | 2031-10-24 | −3 days |
| 2026-09-04 | Trastuzumab Emtansine, Atezolizumab | NCT04873362A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | Phase 3 | 2028-08-31 | 2027-03-31 | −519 days |
| 2026-09-04 | Riociguat, Macitentan | NCT05140525Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH | Phase 3 | 2026-12-31 | 2026-03-26 | −280 days |
| 2026-09-04 | SHR-1819 | NCT06468956Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | Phase 3 | 2026-12-31 | 2026-08-26 | −127 days |
| 2026-09-04 | Letrozole, Inavolisib | NCT06790693A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | 2032-05-30 | 2032-01-31 | −120 days |
| 2026-09-04 | Aflibercept | NCT06668064A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | Phase 3 | 2026-08 | 2026-07-13 | −19 days |
| 2026-09-03 | Pembrolizumab | NCT06790966Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 3 | 2029-02 | 2026-08-25 | −891 days |
| 2026-09-03 | Recaticimab | NCT07002476Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion | Phase 3 | 2028-06-01 | 2027-03-01 | −458 days |
| 2026-09-03 | Pembrolizumab | NCT04534205A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | 2029-04 | 2028-08 | −243 days |
| 2026-09-02 | Methylprednisolone | NCT06496997A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome | Phase 2/3 | 2025-08 | 2025-04-01 | −122 days |
| 2026-09-02 | Rosuvastatin, Enlicitide | NCT07216482A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) | Phase 3 | 2026-08-12 | 2026-08-03 | −9 days |
| 2026-09-01 | Pembrolizumab | NCT02954874Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Phase 3 | 2026-08-31 | 2026-08-03 | −28 days |
| 2026-08-29 | Pembrolizumab | NCT06422806Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | 2035-06-30 | 2032-04-18 | −1168 days |
| 2026-08-29 | Durvalumab | NCT05211895A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Phase 3 | 2028-07-12 | 2026-08-10 | −702 days |
| 2026-08-29 | Ocrelizumab | NCT05999604Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial | Phase 3 | 2029-11 | 2028-05 | −549 days |
| 2026-08-29 | Tislelizumab | NCT04170283A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib | Phase 3 | 2027-11 | 2026-12-31 | −305 days |
| 2026-08-29 | Gemcitabine | NCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | Phase 2/3 | 2027-02 | 2026-12-01 | −62 days |
| 2026-08-28 | elecoglipron | NCT07775404A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus | Phase 3 | 2028-04-20 | 2027-06-04 | −321 days |
| 2026-08-27 | Depemokimab | NCT07671001A Study of Depemokimab in Participants of 6 to 11 Years of Age | Phase 3 | 2029-03-19 | 2027-03-01 | −749 days |
| 2026-08-27 | Rosuvastatin, Laroprovstat | NCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | Phase 2/3 | 2027-02-22 | 2025-07-03 | −599 days |
| 2026-08-27 | Anrikefon (HSK21542) | NCT07186426A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Phase 3 | 2026-03-01 | 2026-02-24 | −5 days |
| 2026-08-26 | Inclisiran | NCT05030428Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Phase 3 | 2027-10-13 | 2027-05-10 | −156 days |
| 2026-08-22 | Ublituximab | NCT05877963Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Phase 3 | 2027-12-01 | 2027-01-21 | −314 days |
| 2026-08-20 | Finerenone | NCT05196035A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | Phase 3 | 2027-05-31 | 2027-04-10 | −51 days |
| 2026-08-20 | Finerenone | NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | Phase 3 | 2028-11-28 | 2028-10-08 | −51 days |
| 2026-08-20 | Alectinib | NCT06624059A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 2026-08-28 | 2026-07-31 | −28 days |
| 2026-08-17 | astegolimab | NCT05878769A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | 2034-07-01 | 2027-06-30 | −2558 days |
| 2026-08-17 | Entrectinib, Crizotinib | NCT04603807A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | Phase 3 | 2028-06-26 | 2026-09-30 | −635 days |
| 2026-08-17 | Tapinarof | NCT07265479A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | Phase 3 | 2028-01 | 2027-08 | −153 days |
| 2026-08-17 | Dexamethasone, Elranatamab, Pomalidomide, Daratumumab | NCT05020236A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Phase 3 | 2026-04-27 | 2026-02-26 | −60 days |
| 2026-08-17 | Pumitamig, Pembrolizumab | NCT06712316Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02) | Phase 2/3 | 2029-02 | 2029-01 | −31 days |
| 2026-08-17 | Benralizumab | NCT06465485STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma | Phase 3 | 2026-05-29 | 2026-05-13 | −16 days |
| 2026-08-11 | Bortezomib, Selinexor | NCT04939142A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | 2025-12-31 | 2024-08-26 | −492 days |
| 2026-08-11 | Psilocybin (COMP360) | NCT05711940Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | Phase 3 | 2026-02 | 2025-11-13 | −80 days |
| 2026-08-08 | Empagliflozin | NCT07107945A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | Phase 3 | 2028-06-26 | 2027-04-16 | −437 days |
| 2026-08-08 | Enlicitide | NCT07216482A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) | Phase 3 | 2026-12-02 | 2026-08-12 | −112 days |
| 2026-08-08 | icotrokinra | NCT06878404A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis | Phase 3 | 2026-07-24 | 2026-05-25 | −60 days |
| 2026-08-08 | Pivekimab Sunirine, Azacitidine, Venetoclax | NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) | Phase 2/3 | 2032-06 | 2032-05 | −31 days |
| 2026-08-08 | Safiglipron (HRS-7535) | NCT06904105A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity | Phase 3 | 2026-05 | 2026-04-17 | −14 days |
| 2026-08-08 | mibavademab, metreleptin | NCT06548100A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) | Phase 3 | 2026-07-14 | 2026-07-09 | −5 days |
| 2026-08-05 | tofacitinib | NCT04624230Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | Phase 3 | 2027-04-14 | 2027-03-17 | −28 days |
Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.